Publications by authors named "Mark J Levis"

68Publications

The Changing Landscape of Treatment in Acute Myeloid Leukemia.

Am Soc Clin Oncol Educ Book 2020 Mar;40:1-12

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_279129DOI Listing
March 2020

A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.

Clin Lymphoma Myeloma Leuk 2020 04 6;20(4):226-233.e1. Epub 2019 Nov 6.

Division of Hematology and Oncology, Department of Medicine, Seidman Cancer Center, Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.10.018DOI Listing
April 2020

Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.

N Engl J Med 2019 10;381(18):1728-1740

From the Abramson Cancer Center, University of Pennsylvania (A.E.P.), and Thomas Jefferson University (M.K.) - both in Philadelphia; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola (G.M.), L. and A. Seràgnoli Institute of Hematology, Bologna University Medical School, Bologna (S.P.), Ospedali Riuniti Villa Sofia-Cervello, Palermo (F.F.), and IRCCS San Raffaele Scientific Institute, Milan (F.C.) - all in Italy; University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Universitätsklinikum Giessen und Marburg, Marburg, Germany (A.N.); Memorial Sloan Kettering Cancer Center, New York (E. Berman); Hospital Universitari i Politècnic La Fe, Valencia, and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto Carlos III, Madrid - both in Spain (P.M.); University of Maryland Greenebaum Comprehensive Cancer Center (M.R.B.) and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (M.J.L.) - both in Baltimore; University of Chicago, Chicago (R.A.L.), and Astellas Pharma, Northbrook (C.L., N. Hasabou, X.L., E. Bahceci) - both in Illinois; University of Minnesota, Minneapolis (C.U.); University of Alabama at Birmingham, Birmingham (H.P.E., A.D.S.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.S.); University of California, San Francisco, San Francisco (R.O.); National Taiwan University, Taipei City, Taiwan (W.-C.C.); Yale University School of Medicine, New Haven, CT (N.P.); Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France (C.R.); Sendai Medical Center, National Hospital Organization, Sendai (H.Y.), and University of Fukui, Fukui (N. Hosono) - both in Japan; Seoul National University (S.-S.Y.) and Asan Medical Center, University of Ulsan College of Medicine (J.-H.L.) - both in Seoul, South Korea; Wake Forest Baptist Medical Center, Winston-Salem, NC (T.P.); and Massachusetts General Hospital, Harvard Medical School, Boston (A.T.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902688DOI Listing
October 2019

Midostaurin for patients with acute myeloid leukemia and FLT3 mutations.

Authors:
Mark J Levis

Clin Adv Hematol Oncol 2019 Jun;17(6):323-325

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
June 2019

Targeting FLT3 mutations in AML: review of current knowledge and evidence.

Leukemia 2019 02 16;33(2):299-312. Epub 2019 Jan 16.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0357-9
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0357-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365380PMC
February 2019

Clinical implications of molecular markers in acute myeloid leukemia.

Eur J Haematol 2019 Jan 23;102(1):20-35. Epub 2018 Oct 23.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13172DOI Listing
January 2019

Advances in targeted therapy for acute myeloid leukaemia.

Br J Haematol 2018 02 28;180(4):484-500. Epub 2017 Nov 28.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801209PMC
February 2018

Emerging molecular predictive and prognostic factors in acute myeloid leukemia.

Leuk Lymphoma 2018 09 2;59(9):2021-2039. Epub 2017 Nov 2.

a Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1393669DOI Listing
September 2018

Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Expert Rev Clin Pharmacol 2017 Nov 10;10(11):1177-1189. Epub 2017 Oct 10.

d National Center for Tumor Diseases , Heidelberg , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2017.1387051DOI Listing
November 2017

Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.

Cancer Res 2017 10 18;77(20):5554-5563. Epub 2017 Sep 18.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-2593DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819342PMC
October 2017

The Future of Targeting FLT3 Activation in AML.

Curr Hematol Malig Rep 2017 06;12(3):153-167

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Cancer Research Building 1, Room 2M44, Baltimore, MD, 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0381-2DOI Listing
June 2017

Are FLT3 inhibitors likely to improve -mutated acute myeloid leukemia in the foreseeable future?

Int J Hematol Oncol 2016 Dec 24;5(4):123-126. Epub 2017 Feb 24.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/ijh-2017-0001
Publisher Site
http://dx.doi.org/10.2217/ijh-2017-0001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171975PMC
December 2016

Carotidynia Heralding the Onset of Acute Leukemia.

Am J Med 2016 Jul 9;129(7):e43-5. Epub 2016 Apr 9.

Thayer Firm, Osler Medical Service, Johns Hopkins Hospital, Baltimore, Md; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2016.03.011DOI Listing
July 2016

A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.

Mol Diagn Ther 2015 Dec;19(6):409-17

Division of Molecular Pathology, Department of Pathology, Johns Hopkins University School of Medicine, Park SB202, 600 North Wolfe Street, Baltimore, MD, 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40291-015-0170-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655128PMC
December 2015

FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.

Semin Hematol 2015 Jul 17;52(3):193-9. Epub 2015 Mar 17.

Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2015.03.004DOI Listing
July 2015

Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.

Biol Blood Marrow Transplant 2014 Dec 23;20(12):1989-95. Epub 2014 Aug 23.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791140053
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2014.08.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253693PMC
December 2014

FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.

Cancer Res 2014 Sep 24;74(18):5206-17. Epub 2014 Jul 24.

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-1028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301261PMC
September 2014

The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.

Ther Adv Hematol 2014 Jun;5(3):65-77

Massachusetts General Hospital, Harvard Medical School, Zero Emerson Place, Suite 118, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620714532123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031904PMC
June 2014

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.

Leuk Lymphoma 2014 Feb 5;55(2):243-55. Epub 2013 Jun 5.

Department of Internal Medicine III, University Hospital of Ulm , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.800198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333682PMC
February 2014

FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Int J Hematol 2013 Jun 24;97(6):683-94. Epub 2013 Apr 24.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-013-1334-8DOI Listing
June 2013

Will newer tyrosine kinase inhibitors have an impact in AML?

Authors:
Mark J Levis

Best Pract Res Clin Haematol 2010 Dec 5;23(4):489-94. Epub 2010 Nov 5.

Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2010.09.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049331PMC
December 2010

Bench to bedside targeting of FLT3 in acute leukemia.

Curr Drug Targets 2010 Jul;11(7):781-9

Department of Oncology, Division of Hematologic Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023996PMC
http://dx.doi.org/10.2174/138945010791320782DOI Listing
July 2010